Skip to main content

Table 2 Changes in cMRI measured RV parameters following treatment for 6 months with either empagliflozin or placebo

From: Impact of empagliflozin on right ventricular parameters and function among patients with type 2 diabetes

  Empagliflozin 10 mg (n = 44)* Placebo (n = 46)*
Baseline 6 months Mean change (95% CI) Baseline 6 months Mean change (95% CI)
RV mass index, g/m2 11.5 (2.35) 11.4 (2.13) − 0.07 (− 0.64 to 0.50) 12.8 (2.37) 11.8 (1.84) − 0.28 (− 0.96 to 0.40)
RV end diastolic volume index, mL/m2 62.0 (13.2) 61.7 (10.8) − 0.53 (− 3.22 to 2.16) 66.4 (12.6) 65.5 (10.4) − 0.84 (− 3.15 to 1.47)
RV end systolic volume index, mL/m2 28.9 (6.51) 28.6 (6.24) − 0.48 (− 1.99 to 1.03) 30.8 (6.98) 30.4 (5.60) − 0.27 (− 1.63 to 1.08)
RV ejection fraction, % 53.2 (4.93) 53.7 (5.17) 0.53 (− 1.02 to 2.08) 53.8 (4.59) 53.5 (5.13) − 0.35 (− 1.82 to 1.12)
  1. RV right ventricle
  2. Data expressed as percentages or mean (standard deviation) unless otherwise specified
  3. *All p-values are non-significant